A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
Information source: Amgen
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myelodysplastic Syndromes; Thrombocytopenia
Intervention: AMG 531 (Biological); Placebo (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Amgen Official(s) and/or principal investigator(s): MD, Study Director, Affiliation: Amgen
Summary
This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG
531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects
with myelodysplastic syndrome (MDS) receiving lenalidomide. Subjects with MDS that are
planned to receive at least four cycles of lenalidomide for treatment of their disease are
appropriate to screen for this study.
All subjects meeting the eligibility criteria will receive lenalidomide 10 mg capsule by
mouth daily every day of each 28-day cycle. Subjects will receive AMG 531 or placebo once a
week by subcutaneous injection for 16 weeks.
Clinical Details
Official title: A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care
Primary outcome: Occurrence of a Clinically Significant Thrombocytopenic Event
Secondary outcome: Lenalidomide Dose Reduction and Delay Due to ThrombocytopeniaAchieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines Platelet Transfusion
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO)
classification
- Low or Intermediate-1 risk category MDS using the IPSS
- Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each
cycle for at least 4 cycles
- Eastern Cooperative Oncology (ECOG) performance status of 0-2
- Subjects must be at least 18 years of age or older
Exclusion Criteria:
- Prior exposure to >3 cycles of lenalidomide
- Exposure to lenalidomide within the last 30 days
- Prior history of leukemia or aplastic anemia
- Prior history of stem cell transplantation
- Prior malignancy (other than in situ cervical cancer or basal cell cancer of the
skin) unless treated with curative intent and without evidence of disease for 3
years before randomization
- Active or uncontrolled infections
- Unstable angina, congestive heart failure [NYHA > class II], uncontrolled
hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent
(within 1 year) myocardial infarction
- History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past
year
- History of venous thrombosis in the past year
- Received IL-11 within 4 weeks of screening
- Less than 4 weeks since receipt of any investigational drug or device
- Have previously received any other thrombopoietic growth factor
- Pregnant or breast feeding
- Subjects of reproductive potential who are not using adequate contraceptive
precautions, in the judgment of the investigator
- Known hypersensitivity to any recombinant E coli-derived product
Locations and Contacts
Additional Information
Notice regarding posted summaries of trial results AmgenTrials clinical trials website
Starting date: December 2006
Last updated: January 20, 2011
|